Decreased lymphocytic proliferation by mitogens in patients with transitional cell carcinoma of the renal pelvis subsequent to non-Hodgkin's lymphoma.
Matano
S
S
Nakamura
S
S
Kobayashi
K
K
Misaki
T
T
Matsuda
T
T
Sugimoto
T
T
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001984:Bronchial Neoplasms / Q000188:drug therapy*; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced / Q000276:immunology*; D003043:Cocarcinogenesis; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology*; D007680:Kidney Neoplasms / Q000139:chemically induced / Q000276:immunology*; D007682:Kidney Pelvis; D008213:Lymphocyte Activation / Q000187:drug effects*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008934:Mitogens / Q000494:pharmacology*; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000276:immunology*; D011239:Prednisolone / Q000008:administration & dosage; D012907:Smoking / Q000009:adverse effects; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
D008934:Mitogens; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D014751:Vindesine